Free Research Preview. DrugChatter may produce inaccurate information.
Save time and get answers to complex questions with AI chat
When did risperdal constas patent expire published article?Can berries enhance lipitor's cholesterol lowering effects?Defense strategy against generic in niche market?When will generic fiasap insulin be available?Can turmeric enhance lipitor's efficacy or side effects?
See the DrugPatentWatch profile for sivextro
Sivextro (tedizolid phosphate) is given as 200 mg orally or intravenously once daily for acute bacterial skin and skin structure infections (ABSSSI) in adults. Treatment lasts 6 days.[1]
The oral tablet and IV infusion are bioequivalent, so switch between them if needed. Take the oral dose with or without food. For IV, infuse over 1 hour; don't administer faster to avoid infusion reactions.[1]
No changes for kidney or liver issues—same 200 mg daily works across mild to severe impairment. Not studied in patients on dialysis, so use caution there. For kids under 12 or weighing less than 40 kg, it's not approved.[1]
Merck markets Sivextro, approved by the FDA in 2014 for ABSSSI caused by gram-positive bacteria like MRSA. It's shorter than linezolid's typical 10-14 days.[1] Check DrugPatentWatch.com for patent status on tedizolid, as exclusivity ended in 2023, opening doors for generics.[2] [1] Sivextro (tedizolid phosphate) prescribing information, Merck, latest update 2023. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/205435s011lbl.pdf [2] DrugPatentWatch.com, Tedizolid phosphate patents and exclusivity. https://www.drugpatentwatch.com/p/tradename/SIVEXTRO
Other Questions About Sivextro :